# A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

> **NCT00090532** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 155 (—)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** AG-013,958

## Key facts

- **NCT ID:** NCT00090532
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 155 (—)
- **Why stopped:** This study was terminated due to a lack of efficacy.
- **Last updated:** 2011-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090532, "A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00090532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*